



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/355 // (A61K 31/355, 31:20) (A61K 31/355, 31:075)	A1	(11) International Publication Number: WO 00/21528 (43) International Publication Date: 20 April 2000 (20.04.00)
(21) International Application Number: PCT/EP99/07626 (22) International Filing Date: 12 October 1999 (12.10.99) (30) Priority Data: 98811021.9 14 October 1998 (14.10.98) EP (71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). (71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT). (72) Inventor; and (75) Inventor/Applicant (for US only): KIS, György, Lajos [CH/CH]; Keberlistrasse 21, CH-8273 Triboltingen (CH). (74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: USE OF OPHTHALMIC COMPOSITION COMPRISING VITAMIN A AND VITAMIN E (57) Abstract The present invention relates to the use of a vitamin cocktail comprising both vitamin A and vitamin E in the preparation of an eye medicament for the protection of the eye against both UV-irradiation and ozone.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

USE OF OPHTHALMIC COMPOSITION COMPRISING VITAMIN A AND VITAMIN E

The present invention relates to the use of a vitamin cocktail comprising both vitamin A and vitamin E in the preparation of an eye medicament for the protection of the eye against both UV-irradiation and ozone.

Eye medicaments comprising both vitamin A and vitamin E are known in the art. These are for example marketed by CIBA-Vision under the trade name Oculotect®-Gel. Oculotect is typically prescribed for the treatment of dry eye or keratoconjunctivitis.

It has now surprisingly been found that an ophthalmic composition comprising both vitamin A and vitamin E is highly useful for protecting an eye, in particular the human eye, both against UV-irradiation and ozone exposure, both being typically permanently present as so called environmental toxins.

The ophthalmic compositions useful for the above identified protective treatment of the eye are administered either as a gel, a thermogel, a liquid eye drop or an ointment. Preferred is a gel, thermogel or a liquid composition. More preferred is a gel or a thermogel.

An ophthalmic composition comprises typically the components disclosed infra.

The present invention relates to the use of an ophthalmic composition, which comprises mandatorily the two active ingredients vitamin E and vitamin A.

Within the terms of the present invention, vitamin A shall denote a compound such as Vitamin A per se (retinol), esters of retinol such as vitamin A acetate, vitamin A palmitate and the like, retinoic acid and retinoic ester such as retinoic acid methyl ester and the like. Preferred are vitamin A acetate and vitamin A palmitate.

Analogously, vitamin E shall denote within the terms of the present invention vitamin E per se, namely (+)- α -tocopherol, isomers and racemates of α -tocopherol such as racemic DL- α -tocopherol, esters of optically pure and/or racemic α -tocopherol such as DL- α -tocopherol acetate, succinate and/or nicotinate, specific derivatives of α -tocopherol

such as D- α -tocopheryl polyethylene glycol 1000 succinate (tocophersolan), tocoretinate (retinoic acid esterified with α -tocopherol, see Merck Index 12 th edition, No. 9639) and the like. Preferred are DL- α -tocopherol acetate, tocophersolan and tocoretinate.

Optionally, a vitamin efficacy enhancing agent is present in an above concerned ophthalmic composition, such as aesculin and/ or a derivative thereof. Aesculin is a natural product and exhibits an excellent topical tolerability as well.

If present, aesculin is typically present in an amount of 0.001 to approximately 10 % by weight, preferably of from 0.05 to 5 % by weight and in particular from 0.01 - 1 % by weight.

An ophthalmic composition in accordance to the present invention is advantageously applied topically to the eye, especially in the form of a gel, a thermogel, a solution, a suspension, or an ointment. Such compositions comprise the above vitamins typically in a range of from approximately 0.0005 to approximately 15.0% by weight, preferably from approximately 0.001 to approximately 10.0% by weight, or more preferably in the range of from approximately 0.05 to approximately 7 % by weight and most preferably in the range of from 0.01 to 1.1 % by weight.

The ratio of a vitamin A to a vitamin E used in an above gel, thermogel or liquid composition is typically from 1 : 10, more preferably from 1 : 5 and in particular of from 1 : 1.

For ointments the ratio of a vitamin A to a vitamin E used is typically from 50 : 1, more preferably from 35 : 1 and in particular of from 20 : 1.

A thermogel denotes a gel which typically exhibits a thermoreversability. A thermogel in accordance to the invention exhibits a viscosity maximum at a temperature in the range of about 30 - 60°C, and more precisely at a temperature of about the body temperature. It comprises preferably a polyethylen-polypropylen block copolymer. A representative example of such a block copolymer is Poloxamer 407 (Lutrol® F 127 from BASF, Germany).

Other customary ophthalmically acceptable excipients and additives known to the person skilled in the art may be comprised in an above composition, for example those of the type

mentioned below, especially carriers, stabilizers, solubilizers, tonicity enhancing agents, buffer substances, preservatives, thickeners, complexing agents and other excipients. Such compositions are prepared in a manner known per se, for example by mixing the active ingredients with the corresponding excipients and/or additives to form corresponding ophthalmic compositions.

Carriers used in accordance to the present invention are preferably suitable for topical administration, and are for example water, mixtures of water and water-miscible solvents, such as C₁- to C₇-alkanols, vegetable oils or mineral oils comprising from 0.5 to 5% by weight hydroxyethylcellulose, ethyl oleate, carboxymethyl-cellulose, polyvinyl-pyrrolidone and other non-toxic water-soluble polymers for ophthalmic uses, such as, for example, cellulose derivatives, such as methylcellulose, alkali metal salts of carboxy-methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, methylhydroxypropyl-cellulose and hydroxypropylcellulose, acrylates or methacrylates, such as salts of polyacrylic acid or ethyl acrylate, polyacrylamides, natural products, such as gelatin, alginates, pectins, tragacanth, karaya gum, xanthan gum, carrageenin, agar and acacia, starch derivatives, such as starch acetate and hydroxypropyl starch, and also other synthetic products, such as polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methyl ether, polyethylene oxide, preferably cross-linked polyacrylic acid, such as neutral Carbopol, or mixtures of those polymers. Preferred carriers are water, cellulose derivatives, such as methylcellulose, alkali metal salts of carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, methylhydroxypropylcellulose and hydroxypropylcellulose, neutral Carbopol, or mixtures thereof. The concentration of the carrier is, for example, from 1 to 100000 times the concentration of the active ingredient.

Carriers and further ingredients used for ointments are known in the art and are typically those described in example 6 *infra*.

The solubilizers used for an ophthalmic composition of the present invention are, for example, tyloxapol, fatty acid glycerol polyethylene glycol esters, fatty acid polyethylene glycol esters, polyethylene glycols, glycerol ethers or mixtures of those compounds. A specific example of an especially preferred solubilizer is a reaction product of castor oil and ethylene oxide, for example the commercial products Cremophor EL[®] or Cremophor RH 40[®]. Reaction products of castor oil and ethylene oxide have proven to be particularly good

solubilizers that are tolerated extremely well by the eye. Another preferred solubilizer is tyloxapol. The concentration used depends especially on the concentration of the active ingredient. The amount added is typically sufficient to solubilize the active ingredient. For example, the concentration of the solubilizer is from 0.1 to 5000 times the concentration of the active ingredient.

Buffers, tonicity enhancing agents and preservatives different from quaternary ammonium salts may be used in an ophthalmic composition of the present invention as well.

Examples of buffer substances are acetate, ascorbate, borate, hydrogen carbonate /carbonate, citrate, gluconate, lactate, phosphate, propionate and TRIS (tromethamine) buffers. Tromethamine and borate buffer are preferred buffers. The amount of buffer substance added is, for example, that necessary to ensure and maintain a physiologically tolerable pH range. The pH range is typically in the range of from 5 to 9, preferably from 5.2 to 8.5 and more preferably from 5.5 to 8.2.

Tonicity enhancing agents are, for example, ionic compounds, such as alkali metal or alkaline earth metal halides, such as, for example, CaCl_2 , KBr, KCl, LiCl, NaI, NaBr or NaCl, or boric acid. Non-ionic tonicity enhancing agents are, for example, urea, glycerol, sorbitol, mannitol, propylene glycol, or dextrose. For example, sufficient tonicity enhancing agent is added to impart to the ready-for-use ophthalmic composition an osmolality of approximately from 50 to 1000 mOsmol, preferred from 100 to 400 mOsmol, more preferred from 200 to 400 mOsmol and even more preferred from 250 to 350 mOsmol.

Examples of preservatives are quaternary ammonium salts such as benzalkonium chloride, benzoxonium chloride or polyquats (polymeric quaternary ammonium salts, being specifically disclosed in the Canadian Patent No. 1'069'522), alkyl-mercury salts of thiosalicylic acid, such as, for example, thiomersal, phenylmercuric nitrate, phenylmercuric acetate or phenylmercuric borate, parabens, such as, for example, methylparaben or propylparaben, alcohols, such as, for example, chlorobutanol, benzyl alcohol or phenyl ethanol, guanidine derivatives, such as, for example, chlorohexidine or polyhexamethylene biguanide, or sorbic acid. Preferred preservatives are quaternary ammonium salts, alkyl-mercury salts and parabens. Where appropriate, a sufficient amount of preservative is

added to the ophthalmic composition to ensure protection against secondary contaminations during use caused by bacteria and fungi.

The ophthalmic compositions may comprise further non-toxic excipients, such as, for example, emulsifiers, wetting agents or fillers, such as, for example, the polyethylene glycols designated 200, 300, 400 and 600, or Carbowax designated 1000, 1500, 4000, 6000 and 10000. Other excipients that may be used if desired are listed below but they are not intended to limit in any way the scope of the possible excipients. They are especially complexing agents, such as disodium-EDTA or EDTA, antioxidants, such as ascorbic acid, acetylcysteine, cysteine, sodium hydrogen sulfite, butyl-hydroxyanisole, butyl-hydroxy-toluene; stabilizers, such as thiourea, thiosorbitol, sodium dioctyl sulfosuccinate or monothioglycerol; or other excipients, such as, for example, lauric acid sorbitol ester, triethanol amine oleate or palmitic acid ester. Preferred excipients are complexing agents, such as disodium-EDTA. The amount and type of excipient added is in accordance with the particular requirements and is generally in the range of from approximately 0.0001 to approximately 90% by weight.

The invention also relates to a method to protect the eye of an individual, preferably a human being, against UV-irradiation and ozone exposure, which method comprises the administration of an ophthalmic composition which comprises both vitamin A and vitamin E to an individual in need therefore. The administration is typically a regular administration, for example one drop 1 to 5 times per day, preferably one drop 1 to 3 times per day, but administration may occur as often as once per hour.

During summer time, both UV-irradiation and ozone exposure reach a level which may be harmful for the eye. The composition of the present invention is able to filter out the harmful UV-irradiation, in particular UV-A and UV-B irradiation. It has surprisingly been found that the combination of a vitamin A and E exhibit a highly UV-protective effect. In addition to said UV protection, an above composition is simultaneously protecting against ozone. Said ozone is typically deactivated by the antioxidative effect of a vitamin E. In addition to the above protecting effect, the ophthalmic compositions described above are extremely well tolerated by the eye which allows frequent use.

The invention will be disclosed more particularly in the following non-limiting examples.

Example 1 (gel)

2 g	Collidon 90 F
1 g	Na ₂ EDTA
15 g	Mowiol (PVA)
0.1 g	benzalkonium chloride (BAK)
ad pH 5.7 - 5.9	boric acid
10 g	vitamin E, water miscible 0.5 g/g
12 g	vitamin A, water miscible 100'000 IU/g
0.1 g	aesculin
ad 1000ml	water deionized

Example 2 (gel)

0.1 g	benzalkonium chloride (BAK)
1 g	Na ₂ EDTA
40 g	Mowiol (PVA)
ad pH 5.7 - 5.9	boric acid
10 g	vitamin E, water miscible 0.5 g/g
12 g	vitamin A, water miscible 100'000 IU/g
0.1 g	aesculin
ad 1000ml	water deionized

Example 3 (thermogel)

0.1 g	benzalkonium chloride (BAK)
1 g	Na ₂ EDTA
150 g	Lutrol F 127
ad pH 5.7 - 5.9	boric acid
10 g	vitamin E, water miscible 0.5 g/g
12 g	vitamin A, water miscible 100'000 IU/g
0.1 g	aesculin
ad 1000ml	water deionized

Example 4 (eye drops)

0.1 g	benzalkonium chloride (BAK)
1 g	Na ₂ EDTA
40 g	Mowiol (PVA)
1.4 g	borax
16.2 g	boric acid
10 g	α -tocopherol acetate, water miscible 0.5 g/g
10 g	vitamin A palmitate, water miscible 100'000 IU/g
4.0 g	methyl hydroxypropyl cellulose
ad 1000ml	water deionized

Example 5 (gel)

0.1 g	cetrimide
0.5 g	Na ₂ EDTA
3.5 g	carbomer 980 (carbopol)
5.9 g	tromethamine
16.0 g	glycerol
10 g	α -tocopherol acetate, water miscible 0.5 g/g
10 g	vitamin A palmitate, water miscible 100'000 IU/g
ad 1000ml	water deionized

Example 6 (ointment)

25.7 g	cetyl stearyl alcohol
164.3 g	wool fat
252.44 g	liquid paraffin
550.7 g	white petrolatum
0.19 g	α -tocopherol, 0.1 mg/g
6.67 g	vitamin A acetate, oily concentrate 1'500'000 IU/g
ad 1000 g	ointment

Example 7 (eye drops)

1 g	Na ₂ EDTA
40 g	Mowiol (PVA)
1.4 g	borax
16.2 g	boric acid
10 g	α -tocopherol acetate, water miscible 0.5 g/g
10 g	vitamin A palmitate, water miscible 100'000 IU/g
4.0 g	methyl hydroxypropyl cellulose
ad 1000ml	water deionized

Example 8 (gel)

0.5 g	Na ₂ EDTA
3.5 g	carbomer 980 (carbopol)
5.9 g	tromethamine
16.0 g	glycerol
10 g	α -tocopherol acetate, water miscible 0.5 g/g
10 g	vitamin A palmitate, water miscible 100'000 IU/g
ad 1000ml	water deionized

Example 9

1.25 g gel of example 5 is diluted in 100 ml of deionized water. This highly diluted solution is investigated by UV-spectroscopy, which demonstrates that the addressed ophthalmic gel exhibits a significant UV-absorption even at low concentration (simulation of the tear dilution effect when administering the gel to the eye).

The UV spectrum is recorded with a Perkin Elmer, Lambda 15 UV/VIS spectrophotometer. Two maxima are recorded, namely at 329.2 nm (0.705 relative absorption) and at 286.4 nm (0.539 relative absorption).

Example 10

The ozone protective effect is investigated by the determination of the ozone degradation in water. Pure deionized water saturated with ozone is used which contains 0.25 ppm ozone. The following table presents data illustrating the decrease in ozone concentration over time

for a 0.25 ppm ozone in water solution without any treatment (1), or with treatment with a gel according to this invention (2), (3) and (4). In said table, column (2) comprises data for a 0.25 ppm ozone in water solution wherein 1 g gel of example 5 per 100 ml water is present, column (3) comprises data for a 0.25 ppm ozone in water solution wherein 2 g gel of example 5 per 100 ml water is present, column (4) comprises data for a 0.25 ppm ozone in water solution wherein 4 g gel of example 5 per 100 ml water is present.

Time	Concentration of Ozone (ppm)			
(min)	(1)	(2)	(3)	(4)
0	0.25	0.25	0.25	0,25
10	0.22	0.16	0.13	0.12
15	0.20	0.14	0.12	0.10
30	0.18	0.14	0.10	0.09
60	0.15	0.10	0.08	0.08

CLAIMS

1. Use of both vitamin A and vitamin E in the preparation of an eye medicament for the protective treatment of the eye against both UV-irradiation and ozone.
2. Use according to claim 1, wherein the eye medicament is a gel, thermogel, eye drop or ointment.
3. Use according to claim 1, wherein the eye medicament further comprises aesculin.
4. Use according to claim 1, wherein the eye medicament further comprises a preservative.
5. Use according to claim 1, wherein the eye medicament further comprises a buffer.
6. Use according to claim 6, wherein the pH is in the range of 5.5 - 8.2.
7. Use according to claim 1, wherein the vitamin A is selected from vitamin A per se (retinol), esters of retinol such as vitamin A acetate, vitamin A palmitate and the like, retinoic acid and retinoic ester such as retinoic acid methyl ester and the like.
8. Use according to of of claim 1, wherein the vitamin E is selected from vitamin E per se, namely (+)- α -tocopherol, isomers and racemates of α -tocopherol such as racemic DL- α -tocopherol, esters of optically pure and/or racemic α -tocopherol such as DL- α -tocopherol acetate, succinate and/or nicotinate, specific derivatives of α -tocopherol such as D- α -tocopheryl polyethylene glycol 1000 succinate (tocophersolan) and tocoretinate (retinoic acid esterified with α -tocopherol).
9. Use according to claim 1, wherein UV-irradiation denotes the wavelength spectrum of UV-A and UV-B (280 - 400nm).
10. A method to protect the eye of an individual against UV-irradiation and ozone exposure, which method comprises the administration of an ophthalmic composition which comprises both vitamin A and vitamin E to an individual in need therefore.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/07626

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/355 //(A61K31/355,31:20), (A61K31/355,31:07)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 571 503 A (MAUSNER JACK) 5 November 1996 (1996-11-05) column 1, line 33-37; example 3 column 2, line 24-33; table III column 12, line 4-24; claim 1	1-3, 5, 6, 8-10
X	EP 0 163 924 A (ISMAIL MOHAMED ROSHDY DR) 11 December 1985 (1985-12-11) page 5, line 3-32; claims 1-4, 6 page 6, line 17-27 page 7, line 7, 8; claims 8-11 page 8, line 30-35; example 20 page 9, line 26 -page 10, line 10	1-5, 8, 9
X	EP 0 473 159 A (SENJU PHARMA CO) 4 March 1992 (1992-03-04) page 4, line 29, 30; claims 1, 3-8	1, 2, 5-9
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 March 2000

Date of mailing of the international search report

06/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Kanbier, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/07626

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 018, no. 639 (C-1282), 6 December 1994 (1994-12-06) & JP 06 247853 A (LION CORP), 6 September 1994 (1994-09-06) abstract	1,2,6,8, 9
A	US 4 999 348 A (ESTEE LAUDER INC.) 12 March 1991 (1991-03-12) column 3, line 41-45; claims 1-4 column 4, line 6-15 column 4, line 30-33	1-3,10
A	WO 97 45105 A (ANGIOTECH PHARMACEUTICALS INC) 4 December 1997 (1997-12-04) page 6, line 2; claims 1,4,13 page 15, line 3-6 page 16, line 11-32 page 27, line 3-8 page 29, line 30 -page 31, line 10	1-3,8,9
A	US 5 002 760 A (KATZEV PHILLIP K) 26 March 1991 (1991-03-26) column 1, line 42-45	1,10
A	US 5 039 513 A (CHATTERJEE RANJIT U ET AL) 13 August 1991 (1991-08-13) column 3, line 34-41 column 3, line 11-14	1,10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/07626

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5571503 A	05-11-1996	NONE	
EP 163924 A	11-12-1985	DE 3416209 A AT 70441 T DE 3584909 A	21-11-1985 15-01-1992 30-01-1992
EP 0473159 A	04-03-1992	AT 119387 T CA 2049822 A DE 69107932 D DE 69107932 T DK 473159 T ES 2069150 T GR 3015340 T JP 5004918 A US 5185372 A	15-03-1995 01-03-1992 13-04-1995 27-07-1995 22-05-1995 01-05-1995 30-06-1995 14-01-1993 09-02-1993
JP 06247853 A	06-09-1994	JP 2939082 B	25-08-1999
US 4999348 A	12-03-1991	CA 1333567 A	20-12-1994
WO 9745105 A	04-12-1997	AU 2760497 A CN 1219872 A EP 0914102 A NO 985463 A	05-01-1998 16-06-1999 12-05-1999 21-01-1999
US 5002760 A	26-03-1991	NONE	
US 5039513 A	13-08-1991	US 4869897 A AT 70436 T AU 2408688 A AU 618894 B AU 5457390 A CA 1334007 A DE 3867027 A EP 0313302 A JP 1265016 A NZ 226664 A	26-09-1989 15-01-1992 27-04-1989 09-01-1992 30-08-1990 17-01-1995 30-01-1992 26-04-1989 23-10-1989 26-03-1991



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/355 // (A61K 31/355, 31:20) (A61K 31/355, 31:07)		A1	(11) International Publication Number: WO 00/21528
			(43) International Publication Date: 20 April 2000 (20.04.00)
<p>(21) International Application Number: PCT/EP99/07626</p> <p>(22) International Filing Date: 12 October 1999 (12.10.99)</p> <p>(30) Priority Data: 98811021.9 14 October 1998 (14.10.98) EP</p> <p>(71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).</p> <p>(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): KIS, György, Lajos [CH/CH]; Keberlistrasse 21, CH-8273 Triboltingen (CH).</p> <p>(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
(54) Title: USE OF OPHTHALMIC COMPOSITION COMPRISING VITAMIN A AND VITAMIN E			
(57) Abstract			
<p>The present invention relates to the use of a vitamin cocktail comprising both vitamin A and vitamin E in the preparation of an eye medicament for the protection of the eye against both UV-irradiation and ozone.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		